#Garadacimab
LightNews LightNews
natrevdrugdiscov.nature.com
FDA approves first factor XIIa inhibitor, for hereditary angioedema nature.com/articles/d41...

CSL's first-in-class monoclonal antibody therapy garadacimab provides a once-monthly preventative option
Screenshot of article
July 14, 2025 at 2:51 PM
ievadr.bsky.social
Another nice example is this publication on garadacimab, where we showed what happened at different FOM concentrations (Fig. S3).
Image taken from the preprint: www.biorxiv.org/content/10.1...
Publication in Structure: www.cell.com/structure/ab...
July 16, 2025 at 7:13 AM
sd-viz.bsky.social
Beginning a journey on bsky exploring a molecular view of biology and medicine. Today's subject is the inhibition of beta FXIIa by garadacimab. Last month this monoclonal antibody was approved by @usfda.bsky.social for treating hereditary angioedema.
structure of coagulation factor beta-XIIa in complex with the garadacimab Fab fragment (pdb_00008r8d)
July 1, 2025 at 10:00 PM
biorxivpreprint.bsky.social
Structural basis for inhibition of βFXIIa by garadacimab https://www.biorxiv.org/content/10.1101/2023.12.03.569829v1
Structural basis for inhibition of βFXIIa by garadacimab https://www.biorxiv.org/content/10.1101/2023.12.03.569829v1
FXIIa is the principal initiator of the plasma contact system and can activate both procoagulant and
www.biorxiv.org
December 5, 2023 at 1:47 AM
ievadr.bsky.social
Garadacimab, a novel, fully human recombinant monoclonal #antibody inhibitor of human-activated Factor XII (FXIIa), has recently completed its Phase 3 trial for the prophylactic treatment of Hereditary Angioedema (HAE) patients with C1-INH deficiency...
November 22, 2024 at 11:31 AM
hcplivenews.bsky.social
From needle-free epinephrine (Anaphylm) to FDA approval of garadacimab for HAE, here are 5 major allergy updates clinicians need to know. Check out our June allergy news recap here: www.hcplive.com/view...
#Allergy #FDA #Anaphylaxis #HAE #CRS #FoodAllergy
Allergy Month in Review: June 2025
This month in review captures 5 allergy news in June, from FDA approvals to phase 3 data.
www.hcplive.com
July 2, 2025 at 1:00 AM
l2plabs.bsky.social
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress KING OF PRUSSIA, Pa., July 27, 2026 /PRNewswire/ -- Global biotechnology leader CSL...
dlvr.it
July 27, 2026 at 1:03 PM
hepinteractions.bsky.social
✨ New comedications added to the drug interaction checker: Garadacimab to Cancer Therapies and Letermovir to Antivirals
July 23, 2026 at 9:42 AM
contemppeds.bsky.social
The FDA has approved CSL's garadacimab-gxii (Andembry) for prophylactic use to prevent attacks of hereditary angioedema ( hashtag#HAE ) in patients 12 years of age and older. #MedSky #Pedsky

Full details and trial data: hubs.li/Q03sqzvX0
FDA approves garadacimab-gxii to prevent HAE attacks in patients aged 12 years, older
Garadacimab-gxii is the only treatment to target factor Xlla for prophylactic use to prevent attacks of HAE in patients aged 12 years and older.
hubs.li
June 17, 2025 at 2:21 PM
idw-online.de
Garadacimab beim hereditären Angioödem: Anhaltspunkt für beträchtlichen Zusatznutzen
Ein indirekter Vergleich zeigt einen starken Rückgang der monatlichen Rate der Attacken und weitere Vorteile. Warum Hersteller ihre Wirkstoffe in dieser In...
weiterlesen
June 2, 2025 at 11:53 AM
drugdocs.bsky.social
FDA clears Andembry (garadacimab-gxii) for hereditary angioedema ≥ 12 yrs. The VANGUARD trial showed over 99% median reduction in attacks; 62% went 6 months attack-free.

Read more: www.pharmacytimes.com/view/garadac...

Find the clinical evidence for Andembry at drugdocs.com/drug/Andembry
June 25, 2025 at 7:02 PM
bibliotecahuvh.bsky.social
Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis link.springer.com/article/10.1... #hvhebron #al [Text complet]
Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis - Advances in Therapy
Introduction Garadacimab (monoclonal antibody inhibiting activated factor XII [FXIIa]) is approved for long-term prophylaxis (LTP) against hereditary angioedema (HAE) attacks. Due to the novelty of FX...
link.springer.com
June 17, 2026 at 6:56 AM
bibliotecahuvh.bsky.social
Sécurité à long terme du garadacimab chez les patients atteints d’angiœdème héréditaire issue de l’étude d’extension en ouvert de phase 3 : analyse intermédiaire sur une période allant jusqu’à 3 ans www.sciencedirect.com/science/arti... #hvhebron #al
Sécurité à long terme du garadacimab chez les patients atteints d’angiœdème héréditaire issue de l’étude d’extension en ouvert de phase 3 : analyse intermédiaire sur une période allant jusqu’à 3 ans
L’angiœdème héréditaire (AOH) se caractérise par des crises récurrentes, imprévisibles et potentiellement mortelles. Garadacimab (anticorps monoclonal…
www.sciencedirect.com
June 5, 2026 at 11:19 AM
bibliotecahuvh.bsky.social
Garadacimab improves long-term health-related quality of life in patients with hereditary angioedema www.ingentaconnect.com/content/ocea... #hvhebron #al
Garadacimab improves long-term health-related quality of life in ...: Ingenta Connect
www.ingentaconnect.com
May 22, 2025 at 2:34 PM
bibliotecahuvh.bsky.social
Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study scientiasalut.gencat.cat/handle/11351... #ScientiaVH
Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study
scientiasalut.gencat.cat
March 10, 2025 at 8:29 AM
4040rec.bsky.social
#NICE #CSL #HAEtherapy #Andembry #garadacimab #PharmaNews #CSLBehring #hereditaryangioedema #HAE #NHS #NICEguidance #NICETAG #FactorXIIainhibitor #HAEpatients #raregeneticdisorder #MHRA #VANGUARDstudy #HAEattacks #HAEUK #AngelaMetcalfe #HAEprevention #EduardoCabas
pharmaphorum.com/news/nice-fi...
NICE finalises support for CSL's HAE therapy Andembry
CSL Behring's Andembry can be used to prevent recurrent attacks of HAE by the NHS, following finalised guidance from reimbursement authority NICE
pharmaphorum.com
October 9, 2025 at 10:00 AM
4040rec.bsky.social
#hereditaryangioedema #HAE #CSL #ANDEMBRY #garadacimab #factorXIIa #hereditaryangioedemaattacks #HAEattacks #factorXIIainhibitor #angioedema #HAEresearch #HAEtreatmentoptimisation #raredisease #geneticdisorder #HAEprevalence #VANGUARDclinicaltrial
pharmatimes.com/news/andembr...
Andembry treatment approved across Europe - PharmaTimes
Significant progress for hereditary angioedema condition
pharmatimes.com
February 18, 2025 at 10:47 AM
4040rec.bsky.social
#CSL #CSLBehring #garadacimab #hereditaryangioedema #HAE #HAEpatients #EMA #CHMP #factorXIIainhibitor #HAEattacks #CHMPdecision #HAEattacks #HAEattackprevention #Phase3clinicaltrial #VANGUARDclinicaltrial #openlabelextensionstudy
pharmatimes.com/news/csl-rec...
CSL receives positive opinion for garadacimab in hereditary angioedema - PharmaTimes
New treatment could revolutionise care for HAE patients
pharmatimes.com
December 16, 2024 at 3:29 PM
medicalxpress.com.web.brid.gy
FDA approves once-monthly Andembry for hereditary angioedema
The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE).
medicalxpress.com
June 21, 2025 at 10:50 AM
fundacionweber.bsky.social
Nuevas terapias, nuevas oportunidades para pacientes con angioedema hereditario (AEH). Avances como berotralstat y garadacimab están transformando el manejo de esta enfermedad rara.

Lee la entrevista a Álvaro Hidalgo👉https://bit.ly/EntrevistaAlvaroHidalgo

#FundaciónWeber #EnfermedadesRaras
May 9, 2025 at 5:31 PM
longtail-news.bsky.social
Feed: "Medical News, Health News Latest, Medical News Today - Medical Dialogues |"
By: Medha Baranwal on Monday, March 9, 2026
Switch to Garadacimab Shows Strong Safety, Zero Hereditary Angioedema Attacks in Interim Study
USA: Switching
medicaldialogues.in
March 9, 2026 at 10:31 PM
longtail-news.bsky.social
Feed: "Latest News | Stock Titan"
Published on Thursday, February 20, 2025
CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) | CSLLY Stock News
First-in-class monoclonal antibody offering monthly subcutaneous treatment for HAE patients. Expands global reach following EU and UK approvals.
www.stocktitan.net
February 20, 2025 at 4:08 PM
marghollingdale.bsky.social
'#CSL312 is also called #Garadacimab and is an antibody treatment that inhibits the plasma protein, FXIIa.

It is hoped the treatment will be useful in preventing the progression of coronavirus once patients experience respiratory distress..'
December 7, 2024 at 9:29 PM
newsen.bsky.social
European Commission Grants Approval for CSL's ANDEMBRY® as a New Treatment for Hereditary Angioedema#Germany#Garadacimab#Marburg#CSL_Behring#ANDEMBRY
European Commission Grants Approval for CSL's ANDEMBRY® as a New Treatment for Hereditary Angioedema
CSL's ANDEMBRY® is now approved by the European Commission as the first monthly treatment for hereditary angioedema, providing hope for patients.
third-news.com
February 13, 2025 at 12:11 PM